MAGEA2 and cancer: Based on our investigation, the BLAST analysis conducted on the selected MAGE-A2-LP displayed notable homology between the chosen LP and some members of the MAGE family, such as MAGE-A3, with 93% homology, indicating that MAGE-A2 could be a potential tumor antigen for cancer immunotherapy.